{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Zinc Washout Period",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -21,
        "relativeTo": "First Dose",
        "windowUpper": -21
      },
      {
        "id": "timing_3",
        "name": "Chelator Therapy Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -4,
        "relativeTo": "First Dose",
        "windowUpper": -4
      },
      {
        "id": "timing_4",
        "name": "Tetrathiomolybdate Washout",
        "type": "Within",
        "unit": "years",
        "instanceType": "Timing",
        "value": -1,
        "relativeTo": "First Dose",
        "windowUpper": -365
      },
      {
        "id": "timing_5",
        "name": "Experimental Therapy Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -90,
        "relativeTo": "Screening",
        "windowUpper": -90
      },
      {
        "id": "timing_6",
        "name": "Prescription Medication Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -14,
        "windowUpper": -14
      },
      {
        "id": "timing_7",
        "name": "Non-Prescription Medication Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "windowUpper": -7
      },
      {
        "id": "timing_8",
        "name": "Alcohol Washout",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": -48,
        "relativeTo": "First Dose",
        "windowUpper": -48
      },
      {
        "id": "timing_9",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_10",
        "name": "Post-Dose Meal Delay",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "windowLower": 2
      },
      {
        "id": "timing_11",
        "name": "Pre-Dose Fasting",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 10,
        "windowLower": -10,
        "windowUpper": 0
      },
      {
        "id": "timing_12",
        "name": "Pregnancy Test Interval",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_13",
        "name": "Abnormal Lab Repeat Testing Interval",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 1
      },
      {
        "id": "timing_14",
        "name": "Outpatient Period Extension",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "windowLower": 0,
        "windowUpper": 14
      },
      {
        "id": "timing_15",
        "name": "Dose Escalation Timing",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Dose Escalation Safety Review",
        "instanceType": "Condition",
        "description": "Safety data must be reviewed by the Safety Review Committee before dose escalation.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "Moderate Transaminase Elevation",
        "instanceType": "Condition",
        "description": "Criteria for temporary dose interruption due to liver enzyme elevation.",
        "text": "ALT or AST > 3 x ULN and <= 5 x ULN"
      },
      {
        "id": "cond_3",
        "name": "Severe Transaminase Elevation",
        "instanceType": "Condition",
        "description": "Criteria for permanent discontinuation due to severe liver enzyme elevation.",
        "text": "ALT or AST > 5 x ULN"
      },
      {
        "id": "cond_4",
        "name": "Significant Hemoglobin Decrease",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to a drop in hemoglobin.",
        "text": "Hemoglobin > 2 g/dL decrease from baseline"
      },
      {
        "id": "cond_5",
        "name": "Significant Platelet Decrease",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to a drop in platelets.",
        "text": "Platelets > 30% decrease from baseline"
      },
      {
        "id": "cond_6",
        "name": "Significant Neutrophil Decrease",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to a drop in neutrophils.",
        "text": "Neutrophils > 30% decrease from baseline and below reference range at baseline"
      },
      {
        "id": "cond_7",
        "name": "Potential Hy's Law",
        "instanceType": "Condition",
        "description": "Criteria for temporary dose interruption due to concurrent bilirubin and ALT elevation.",
        "text": "Bilirubin > 2 x ULN accompanied by ALT > 3 x ULN"
      },
      {
        "id": "cond_8",
        "name": "Neurological Worsening",
        "instanceType": "Condition",
        "description": "Clinical evidence of neurological worsening requiring evaluation for dose modification.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_9",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Clinical evidence of psychiatric worsening requiring evaluation for dose modification.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_10",
        "name": "Discontinuation Events",
        "instanceType": "Condition",
        "description": "List of events that require consideration for discontinuation from study intervention.",
        "text": "Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Escalation to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "On Day 29, participants will be titrated up to 30 mg/day, following a satisfactory safety review of data through Day 23."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for Moderate LFT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "current_dose",
        "toElementId": "dose_hold",
        "text": "Temporarily interrupt dosing if ALT or AST > 3x ULN and <= 5x ULN. Rechallenge at 15 mg QOD when ALT/AST < 2x ULN."
      },
      {
        "id": "trans_3",
        "name": "Discontinuation for Severe LFT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "current_dose",
        "toElementId": "discontinued",
        "text": "Discontinue study intervention if ALT or AST > 5x ULN."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Hematologic Toxicity",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "current_dose",
        "toElementId": "reduced_dose",
        "text": "Reduce dose to previous level (or 15mg QOD if on 15mg QD) if Hemoglobin drops >2 g/dL, or Platelets or Neutrophils drop >30% from baseline."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Potential Hy's Law",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "current_dose",
        "toElementId": "dose_hold",
        "text": "Temporarily interrupt dosing if Bilirubin > 2x ULN and ALT > 3x ULN. Rechallenge at 15 mg QOD when bilirubin is below ULN."
      },
      {
        "id": "trans_6",
        "name": "Dose Modification for Neurologic/Psychiatric Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "current_dose",
        "toElementId": "modified_dose",
        "text": "Investigator and Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on neurologic or psychiatric worsening."
      },
      {
        "id": "trans_7",
        "name": "Discontinuation for Specific Safety Events",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "fromElementId": "current_dose",
        "toElementId": "discontinued",
        "text": "Participants must be considered for discontinuation from study intervention for: Serious hypersensitivity reaction, Severe uncontrolled infection, Use of disallowed medication, or Pregnancy."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities."
      },
      {
        "id": "exit_2",
        "name": "Participant Voluntary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor Termination of Study",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Escalation Decision",
        "timepointId": "Day 29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point on Day 29 to escalate dose from 15mg to 30mg, contingent on SRC safety review of data through Day 23.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Liver Function Dose Modification Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing decision-making based on liver function test results to determine if dose interruption or discontinuation is required.",
        "conditionIds": [
          "cond_2",
          "cond_3",
          "cond_7"
        ]
      },
      {
        "id": "dec_3",
        "name": "Hematology Dose Modification Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing decision-making based on complete blood count results to determine if dose reduction is required.",
        "conditionIds": [
          "cond_4",
          "cond_5",
          "cond_6"
        ]
      },
      {
        "id": "dec_4",
        "name": "Clinical Worsening Dose Modification Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing decision-making based on clinical assessment of neurologic or psychiatric status to determine if dose modification is required.",
        "conditionIds": [
          "cond_8",
          "cond_9"
        ]
      }
    ],
    "summary": {
      "timingCount": 15,
      "conditionCount": 10,
      "transitionRuleCount": 7,
      "exitCount": 5
    }
  }
}